ESMO 2022 Conference Coverage


 

ESMO 2022 on the IPSOS Phase 3 Study: 1L Atezo vs. Single-Agent Chemo in Patients With NSCLC Not Eligible for a Platinum-Containing Regimen

71 views
September 30, 2022
Comments 0
Login to view comments. Click here to Login